A Phase 2 interventional study of Elsubrutinib and Placebo for Elsubrutinib in Systemic Lupus Erythematosus (SLE), sponsored by AbbVie. Completed at 87 sites in 18 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 121st largest by enrollment of the 407 interventional ones that give a count, is one of 15 that started in 2020, is one of 120 in phase 2, and was the 311th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 8 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will evaluate how well elsubrutinib and upadacitinib given alone or as the ABBV-599 combination (elsubrutinib/upadacitinib) works within the body, in participants who completed study M19-130. This study will assess the change in disease symptoms.
ABBV-599 is an investigational drug being developed for the treatment of Systemic Lupus Erythematosus (SLE). This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants into 1 of 4 groups called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of SLE will be enrolled. Around 260 participants will be enrolled in the study in approximately 100 sites worldwide.
Participants will receive the following for up to 56 weeks:
Participants will receive oral elsubrutinib capsules and/or oral upadacitinib tablets once daily for up to 56 weeks. Participants who were receiving elsubrutinib and/or upadacitnib in M19-130 will continue to receive the same treatment in this study. Participants who were receiving placebo in M19-130 will be re-randomized to one of the 2 combination treatment arms in this study.
Arm 1: Elsubrutinib Dose A and Upadacitinib Dose A Arm 2: Elsubrutinib Dose A and Upadacitinib Dose B
There may be higher burden for participants in this trial compared to their standard of care. Participants will attend monthly visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received elsubrutinib 60 mg capsules once a day by mouth and upadacitinib 30 mg film-coated tablets once a day by mouth for 48 weeks in Study M19-130. Participants continued on this regimen in the current study (M20-186) for up to 56 weeks.
Drug: Elsubrutinib · Drug: Upadacitinib
Participants received placebo capsules for elsubrutinib once a day by mouth and upadacitinib 30 mg film-coated tablets once a day by mouth for 48 weeks in Study M19-130. Participants continued on this regimen in the current study (M20-186) for up to 56 weeks.
Drug: Placebo for Elsubrutinib · Drug: Upadacitinib
Participants received placebo capsules for elsubrutinib once a day by mouth and placebo film-coated tablets for upadacitinib once a day by mouth for 48 weeks in Study M19-130. Participants received elsubrutinib 60 mg capsules once a day by mouth and upadacitinib 30 mg film-coated tablets once a day in the current study (M20-186) for up to 56 weeks.
Drug: Elsubrutinib · Drug: Upadacitinib
Participants received elsubrutinib 60 mg capsules once a day by mouth and upadacitinib 15 mg film-coated tablets once a day by mouth for 48 weeks in Study M19-130. Participants continued on this regimen in the current study (M20-186) for up to 56 weeks.
Drug: Elsubrutinib · Drug: Upadacitinib
Participants received elsubrutinib 60 mg capsules once a day by mouth and placebo film-coated tablets for upadacitinib once a day by mouth for 48 weeks in Study M19-130. Participants continued on this regimen in the current study (M20-186) for up to 56 weeks.
Drug: Elsubrutinib · Drug: Placebo for Upadacitinib
Participants received placebo capsules for elsubrutinib once a day by mouth and placebo film-coated tablets for upadacitinib once a day by mouth for 48 weeks in Study M19-130. Participants received elsubrutinib 60 mg capsules once a day by mouth and upadacitinib 15 mg film-coated tablets once a day by mouth for 48 weeks in the current study (M20-186) for up to 56 weeks.
Drug: Elsubrutinib · Drug: Upadacitinib
Capsule; Oral
Also known as: ABBV-105
Capsule; Oral
Film-coated tablet; Oral
Also known as: ABT-494, RINVOQ
Film-coated tablet; Oral
Number of Participants With Treatment-Emergent Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs) are defined as an adverse event with an onset date that is on or after the first dose of study drug from Study M20-186, and no more than 30 days after the last dose of study drug from Study M20-186. For more details on adverse events please see the Adverse Event section.
Time frame: From the first dose of study drug in Study M20-186 up to 30 days after the last dose of study drug, up to 442 days
Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4
SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline in Study M19-130: * ≥4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.
Time frame: Baseline of Study M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104
Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Combined Lupus Assessment (BICLA) Response
BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.
Time frame: Baseline of Study M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104
Change From Baseline in Daily Prednisone Dose Over Time
Participants'current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.
Time frame: Baseline of M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104
Number of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLE Disease Activity Index (SLEDAI) Flare Index Through Week 104
The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.
Time frame: From Week 56 through Week 104
| Milestone | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose | Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose |
|---|---|---|---|---|---|---|
| Started | 45 | 47 | 35 | 19 | 25 | 14 |
| Completed | 41 | 38 | 31 | 6 | 1 | 1 |
| Not completed | 4 | 9 | 4 | 13 | 24 | 13 |
| Withdrew: Adverse event | 1 | 0 | 1 | 1 | 0 | 3 |
| Withdrew: Withdrawal by subject | 2 | 7 | 2 | 1 | 1 | 0 |
| Withdrew: Other, not specified | 1 | 2 | 1 | 0 | 0 | 1 |
| Withdrew: Sponsor decision based on interim analysis data review | 0 | 0 | 0 | 11 | 23 | 9 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs) are defined as an adverse event with an onset date that is on or after the first dose of study drug from Study M20-186, and no more than 30 days after the last dose of study drug from Study M20-186. For more details on adverse events please see the Adverse Event section.
| participants | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose | Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose |
|---|---|---|---|---|---|---|
| Any TEAE | 34 | 31 | 30 | 11 | 11 | 7 |
| TESAE | 5 | 5 | 1 | 2 | 1 | 2 |
SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline in Study M19-130: * ≥4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.
| percentage of participants | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose |
|---|---|---|---|
| Week 56 | 71.1 (57.9 to 84.4) | 76.1 (63.8 to 88.4) | 54.3 (37.8 to 70.8) |
| Week 64 | 70.5 (57.0 to 83.9) | 75.6 (63.0 to 88.1) | 58.8 (42.3 to 75.4) |
| Week 72 | 80.5 (68.4 to 92.6) | 88.9 (79.7 to 98.1) | 64.7 (48.6 to 80.8) |
| Week 80 | 75.0 (61.6 to 88.4) | 82.2 (71.1 to 93.4) | 57.6 (40.7 to 74.4) |
| Week 88 | 82.5 (70.7 to 94.3) | 85.7 (75.1 to 96.3) | 48.5 (31.4 to 65.5) |
| Week 96 | 82.9 (71.4 to 94.4) | 76.9 (63.7 to 90.1) | 62.5 (45.7 to 79.3) |
| Week 104 | 85.4 (74.5 to 96.2) | 82.1 (70.0 to 94.1) | 61.3 (44.1 to 78.4) |
BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.
| percentage of participants | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose |
|---|---|---|---|
| Week 56 | 73.3 (60.4 to 86.3) | 67.4 (53.8 to 80.9) | 60.0 (43.8 to 76.2) |
| Week 64 | 75.0 (62.2 to 87.8) | 84.4 (73.9 to 95.0) | 55.9 (39.2 to 72.6) |
| Week 72 | 73.2 (59.6 to 86.7) | 88.9 (79.7 to 98.1) | 61.8 (45.4 to 78.1) |
| Week 80 | 70.0 (55.8 to 84.2) | 77.8 (65.6 to 89.9) | 57.6 (40.7 to 74.4) |
| Week 88 | 80.0 (67.6 to 92.4) | 85.7 (75.1 to 96.3) | 57.6 (40.7 to 74.4) |
| Week 96 | 78.0 (65.4 to 90.7) | 76.9 (63.7 to 90.1) | 59.4 (42.4 to 76.4) |
| Week 104 | 78.0 (65.4 to 90.7) | 69.2 (54.7 to 83.7) | 54.8 (37.3 to 72.4) |
Participants'current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.
| mg | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose |
|---|---|---|---|
| Week 56 | -3.9 ± 5.96 | -3.5 ± 5.99 | -4.9 ± 6.99 |
| Week 64 | -4.2 ± 5.51 | -3.7 ± 5.97 | -5.0 ± 6.87 |
| Week 72 | -4.0 ± 6.59 | -4.9 ± 7.23 | -5.2 ± 6.88 |
| Week 80 | -5.1 ± 5.96 | -4.4 ± 8.05 | -5.2 ± 6.88 |
| Week 88 | -5.5 ± 5.83 | -5.2 ± 6.02 | -6.2 ± 7.04 |
| Week 96 | -5.5 ± 5.88 | -5.7 ± 5.78 | -7.3 ± 6.54 |
| Week 104 | -5.8 ± 6.02 | -5.5 ± 5.65 | -7.7 ± 6.64 |
The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.
| Events per patient-year | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose |
|---|---|---|---|
| Mild/Moderate | 0.62 (0.39 to 0.84) | 1.41 (1.06 to 1.75) | 1.39 (0.99 to 1.78) |
| Severe | 0.00 (0.00 to 0.00) | 0.04 (-0.02 to 0.10) | 0.17 (0.03 to 0.31) |
| Overall | 0.62 (0.39 to 0.84) | 1.45 (1.10 to 1.80) | 1.56 (1.14 to 1.97) |
Collected over All-cause mortality and adverse events were collected from the time informed consent was signed through the end of the study. Median time on follow-up was for 422 days for the ABBV-599 High -> ABBV-599 High group; 423 days for the Upa -> Upa and Pbo -> ABBV-599 High groups; 245 days for the ABBV-599 Low -> ABBV-599 Low group; 163 days for the Els -> Els group; and 142.5 days for the Pbo -> ABBV-599 Low group.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | 0/45 (0%) | 5/45 (11.1%) | 24/45 (53.3%) |
| Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | 0/47 (0%) | 5/47 (10.6%) | 18/47 (38.3%) |
| Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose | 0/35 (0%) | 1/35 (2.9%) | 30/35 (85.7%) |
| ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose | 0/19 (0%) | 2/19 (10.5%) | 11/19 (57.9%) |
| Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo | 0/25 (0%) | 1/25 (4%) | 4/25 (16%) |
| Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose | 0/14 (0%) | 2/14 (14.3%) | 6/14 (42.9%) |
| Event | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose | Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose |
|---|---|---|---|---|---|---|
| SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders | 0/45 | 0/47 | 0/35 | 0/19 | 0/25 | 1/14 |
| UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/45 | 0/47 | 0/35 | 0/19 | 0/25 | 1/14 |
| SKULL FRACTURED BASEInjury, poisoning and procedural complications | 0/45 | 0/47 | 0/35 | 1/19 | 0/25 | 0/14 |
| SUBDURAL HAEMATOMAInjury, poisoning and procedural complications | 0/45 | 0/47 | 0/35 | 1/19 | 0/25 | 0/14 |
| TRAUMATIC INTRACRANIAL HAEMORRHAGEInjury, poisoning and procedural complications | 0/45 | 0/47 | 0/35 | 1/19 | 0/25 | 0/14 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 0/45 | 0/47 | 0/35 | 1/19 | 0/25 | 0/14 |
| CEREBRAL HAEMATOMANervous system disorders | 0/45 | 0/47 | 0/35 | 1/19 | 0/25 | 0/14 |
| NERVOUS SYSTEM DISORDERNervous system disorders | 0/45 | 0/47 | 0/35 | 1/19 | 0/25 | 0/14 |
| GASTROENTERITISInfections and infestations | 0/45 | 0/47 | 0/35 | 0/19 | 1/25 | 0/14 |
| LUMBAR RADICULOPATHYNervous system disorders | 0/45 | 0/47 | 1/35 | 0/19 | 0/25 | 0/14 |
| Event | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose | Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 8/45 | 11/47 | 7/35 | 0/19 | 1/25 | 0/14 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 4/45 | 3/47 | 6/35 | 0/19 | 1/25 | 0/14 |
| URINARY TRACT INFECTIONInfections and infestations | 7/45 | 3/47 | 6/35 | 3/19 | 1/25 | 1/14 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 0/45 | 0/47 | 0/35 | 2/19 | 0/25 | 0/14 |
| HYPERTENSIONVascular disorders | 1/45 | 1/47 | 0/35 | 2/19 | 0/25 | 1/14 |
| PRURITUSSkin and subcutaneous tissue disorders | 4/45 | 0/47 | 0/35 | 0/19 | 0/25 | 0/14 |
| MIGRAINENervous system disorders | 0/45 | 0/47 | 3/35 | 0/19 | 0/25 | 0/14 |
| ANAEMIABlood and lymphatic system disorders | 1/45 | 0/47 | 0/35 | 0/19 | 0/25 | 1/14 |
| DRY EYEEye disorders | 0/45 | 0/47 | 0/35 | 0/19 | 0/25 | 1/14 |
| GASTRITISGastrointestinal disorders | 1/45 | 0/47 | 1/35 | 0/19 | 0/25 | 1/14 |
Full Analysis Set (FAS): all participants who received at least 1 dose of study drug in Study M20-186. Participants are grouped according to treatment sequence as randomized for Studies M19-130 and M20-186. Per protocol, demographic and baseline characteristics are summarized as measured at the start of Study M19-130.
| Age, Continuous(years) | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose | Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose | Total |
|---|---|---|---|---|---|---|---|
| Mean | 42.8 ± 11.39 | 42.5 ± 12.00 | 40.6 ± 11.75 | 38.3 ± 10.52 | 41.2 ± 11.60 | 42.5 ± 11.57 | 41.6 ± 11.50 |
| Sex: Female, Male(Participants) | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose | Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose | Total |
|---|---|---|---|---|---|---|---|
| Female | 42 | 42 | 35 | 18 | 24 | 14 | 175 |
| Male | 3 | 5 | 0 | 1 | 1 | 0 | 10 |
| Race (NIH/OMB)(Participants) | ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose | Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose | ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose | Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo | Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 2 | 1 | 2 | 0 | 8 |
| Asian | 6 | 10 | 12 | 6 | 3 | 2 | 39 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 6 | 0 | 1 | 1 | 1 | 11 |
| White | 32 | 26 | 20 | 10 | 16 | 10 | 114 |
| More than one race | 2 | 5 | 1 | 1 | 3 | 1 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jul 2020 to primary completion in Jan 2024, 41 months.
Results were first posted in Jan 2025, 1 year after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 41 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elsubrutinib · Upadacitinib
Lupus Erythematosus, Systemic →